ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0875

Predictive Biomarkers of Tofacitinib Response and Disease Activity in Juvenile Idiopathic Arthritis Subtypes: A Longitudinal Study
Abstract Number: 0876

Investigation of Predictive Factors for Active Disease Status Within 24 Months of Juvenile Idiopathic Arthritis Diagnosis
Abstract Number: 0877

Neutrophils Extracellular Traps Formation May Serve as a Biomarker for Disease Activity in Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 0878

A United States Nationwide Analysis of Total Knee Arthroplasty in Patients < 21 Years Old
Abstract Number: 0879

Golimumab for Treatment of Polyarticular Juvenile Idiopathic Arthritis – Safety and Effectiveness Updates from a Comparative Study
Abstract Number: 0880

Impact of Characteristic Inflammatory and Structural Imaging Lesions on Expert Classification of Axial Juvenile Spondyloarthritis
Abstract Number: 0881

Social Cognitive Correlates of Accelerometer-measured and Self-reported Physical Activity in Persons with Systemic Lupus Erythematosus
Abstract Number: 0882

Gender Differences in Rheumatology Authorship: A Bibliometric Analysis of High Impact Rheumatology Journals from 2019-2021
Abstract Number: 0883

Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis
Abstract Number: 0884

Serum Calprotectin Can Differentiate Between Sustained Remission and Low Disease Activity States in Rheumatoid Arthritis
Abstract Number: 0885

Association Between Changes in Inflammatory Pathways Associated with a Reduction in CV Risk: Results from the LiiRA Study
Abstract Number: 0886

Incidence of Depression and Anxiety in Rheumatoid Arthritis Patients over Three Decades: A Population-Based Study
Abstract Number: 0887

Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database
Abstract Number: 0888

Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)
Abstract Number: 0889

Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].